These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31650490)

  • 1. Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar.
    Lerch TF; Sharpe P; Mayclin SJ; Edwards TE; Polleck S; Rouse JC; Zou Q; Conlon HD
    BioDrugs; 2020 Feb; 34(1):77-87. PubMed ID: 31650490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
    Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
    Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
    McClellan JE; Conlon HD; Bolt MW; Kalfayan V; Palaparthy R; Rehman MI; Kirchhoff CF
    Therap Adv Gastroenterol; 2019; 12():1756284819852535. PubMed ID: 31223341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
    Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
    MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
    Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
    Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PF-06438179/GP1111: An Infliximab Biosimilar.
    Al-Salama ZT
    BioDrugs; 2018 Dec; 32(6):639-642. PubMed ID: 30284704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
    Vimpolsek M; Gottar-Guillier M; Rossy E
    Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
    Palaparthy R; Rehman MI; von Richter O; Yin D
    Expert Opin Biol Ther; 2019 Oct; 19(10):1065-1074. PubMed ID: 31284794
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
    Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
    MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade
    Derzi M; Johnson TR; Shoieb AM; Conlon HD; Sharpe P; Saati A; Koob S; Bolt MW; Lorello LG; McNally J; Kirchhoff CF; Smolarek TA; Leach MW
    Adv Ther; 2016 Nov; 33(11):1964-1982. PubMed ID: 27585978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
    Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
    MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical characterization of Remsima.
    Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
    MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
    MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
    Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
    RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
    MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.